Advertisement
ASND vs RYTM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Hold and RYTM is a StrongBuy.
ASND's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ASND turned positive on October 09, 2026. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in 45 of 56 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ASND as a result. In 68 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
ASND moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ASND crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in 183 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 97 of 126 cases where ASND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for ASND moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
ASND broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.761) is normal, around the industry mean (3.498). P/E Ratio (21.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.970) is also within normal values, averaging (440.869).
Momentum Indicator for RYTM turns positive, indicating new upward trend
RYTM saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 63 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
RYTM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +1.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 236 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for RYTM moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 21 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for RYTM moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
RYTM broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (75.068) is slightly higher than the industry average of (3.498). P/E Ratio (-35.987) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ASND | RYTM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 42 | 13 | |
SMR RATING 1..100 | 12 | 100 | |
PRICE GROWTH RATING 1..100 | 43 | 40 | |
P/E GROWTH RATING 1..100 | 73 | 55 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ASND's Valuation (89) in the Biotechnology industry is in the same range as RYTM (92). This means that ASND’s stock grew similarly to RYTM’s over the last 12 months.
RYTM's Profit vs Risk Rating (13) in the Biotechnology industry is in the same range as ASND (42). This means that RYTM’s stock grew similarly to ASND’s over the last 12 months.
ASND's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for RYTM (100). This means that ASND’s stock grew significantly faster than RYTM’s over the last 12 months.
RYTM's Price Growth Rating (40) in the Biotechnology industry is in the same range as ASND (43). This means that RYTM’s stock grew similarly to ASND’s over the last 12 months.
RYTM's P/E Growth Rating (55) in the Biotechnology industry is in the same range as ASND (73). This means that RYTM’s stock grew similarly to ASND’s over the last 12 months.
| ASND | RYTM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 84% |
| MACD ODDS (%) | 2 days ago 80% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 75% |
| Advances ODDS (%) | 3 days ago 70% | 2 days ago 81% |
| Declines ODDS (%) | 10 days ago 72% | about 1 month ago 73% |
| BollingerBands ODDS (%) | 1 day ago 61% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ASND’s FA Score shows that 1 FA rating(s) are green while RYTM’s FA Score has 1 green FA rating(s).
- ASND’s FA Score: 1 green, 4 red.
- RYTM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ASND’s TA Score shows that 6 TA indicator(s) are bullish while RYTM’s TA Score has 5 bullish TA indicator(s).
- ASND’s TA Score: 6 bullish, 4 bearish.
- RYTM’s TA Score: 5 bullish, 6 bearish.
Price Growth
ASND (@Biotechnology) experienced а +0.52% price change this week, while RYTM (@Biotechnology) price change was +1.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ASND is expected to report earnings on Nov 12, 2026.
RYTM is expected to report earnings on Mar 03, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ASND and
Correlation & Price change
A.I.dvisor indicates that over the last year, ASND has been loosely correlated with PTGX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then PTGX could also see price increases.
| Ticker / NAME | Correlation To ASND | 1D Price Change % | ||
|---|---|---|---|---|
| ASND | 100% | +1.05% | ||
| PTGX - ASND | 38% Loosely correlated | -1.03% | ||
| RYTM - ASND | 37% Loosely correlated | -1.57% | ||
| ORMP - ASND | 37% Loosely correlated | +4.03% | ||
| AMRN - ASND | 35% Loosely correlated | -0.34% | ||
| TARS - ASND | 35% Loosely correlated | +3.97% | ||
More | ||||
RYTM and
Correlation & Price change
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with SRRK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then SRRK could also see price increases.
| Ticker / NAME | Correlation To RYTM | 1D Price Change % | ||
|---|---|---|---|---|
| RYTM | 100% | -1.57% | ||
| SRRK - RYTM | 51% Loosely correlated | -2.92% | ||
| XNCR - RYTM | 45% Loosely correlated | +1.47% | ||
| GERN - RYTM | 44% Loosely correlated | +4.70% | ||
| VIR - RYTM | 43% Loosely correlated | -0.15% | ||
| BNTC - RYTM | 43% Loosely correlated | +2.05% | ||
More | ||||